A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase
Journal of Medicinal Chemistry · 25.09.2025 · 68 (18) · 19303-19330
DOI: 10.1021/acs.jmedchem.5c01412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.09.2025. Verfasst von Jin Kyeong Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Acinetobacter baumannii, Adenylate Kinase, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: Korea National Institute of Health, Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
We explored the lipopolysaccharide-binding properties of adenylate kinase from Mycobacterium tuberculosis (MtAdk) to facilitate the design of novel peptide antibiotics. Notably, we de novo designed 11-mer peptides derived from the AMP-binding domain (Lys44 to Asp54) of MtAdk. Among 71 designed peptides, DD-S067 was the most effective, especially against carbapenem-resistant Acinetobacter baumannii (CRAB), with minimal development of drug resistance. DD-S067 exhibited multiple antibacterial mechanisms, including disrupting both the outer and inner bacterial membranes, and inducing reactive oxygen species that trigger lipid peroxidation. Transcriptome analysis revealed that DD-S067 disrupted key cellular pathways in CRAB by inhibiting the electron transport chain and triggering oxidative stress responses, ultimately suppressing CRAB virulence mechanisms. Furthermore, DD-S067 exhibited significant protective effects in a CRAB-induced septic shock mouse model, highlighting its potential as a novel peptide antibiotic for treating Gram-negative infections. These findings pave the way for innovative strategies in developing protein-based antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
- Biopharmaceutical Research Center, Korea Basic Science Institute, Cheongju, Chungcheongbuk-do 28119, Republic of Korea.
- Center for Bio-imaging & Translational Research, Korea Basic Science Institute, Cheongju, Chungcheongbuk-do 28119, Republic of Korea.
ORCID-Profile: Jin Kyeong Lee, Yangmee Kim
Förderung
- Korea National Institute of Health
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Lee, J. K., Lee, C. Y., Son, M., Kim, B., Jeong, J., Lee, Y., Lee, W. C., Hwang, E., Kim, E., Jeong, M. S., & Kim, Y. (2025). A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase. Journal of Medicinal Chemistry, 68(18), 19303-19330. https://doi.org/10.1021/acs.jmedchem.5c01412
Vancouver
Lee JK, Lee CY, Son M, Kim B, Jeong J, Lee Y, et al. A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase. Journal of Medicinal Chemistry. 2025;68(18):19303-19330. doi:10.1021/acs.jmedchem.5c01412
BibTeX
@article{Lee2025,
author = {Lee, Jin Kyeong and Lee, Chae Yeong and Son, Minwon and Kim, Byeongkwon and Jeong, Junho and Lee, Yeongjoon and Lee, Woo Cheol and Hwang, Eunha and Kim, Eunhee and Jeong, Myeong Seon and Kim, Yangmee},
title = {A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {18},
pages = {19303--19330},
doi = {10.1021/acs.jmedchem.5c01412}
}
EUVIMED